Smith Sherrell

EVP Smith Sherrell sells 50,000 UTI shares at $33.84 (-6.7% from 52-week high, after +37.2% 90-day rally)

Smith Sherrell, Chief Academic Officer, sold 50,000 shares (54.8% of his pre-transaction holdings) at $33.84 on 2025-05-12, reducing his stake from 91,219 to 41,219 shares. The sale occurred after UTI stock gained 37.2% over 90 days and 25.6% over 30 days, with the transaction price 6.7% below the 52-week high of $37.50. His prior trades at UTI (three measurable sales: 2025-03-19, 2025-03-19, 2025-03-20) were followed by positive 90-day returns (+19.1%, +19.1%, +24.7%), indicating a pattern of selling before subsequent gains rather than before declines. His cross-ticker sell history shows a 0.00% well-timed rate with an average 90-day return of +23.0%, suggesting his sales have historically not preceded price weakness. The company's fundamentals remain solid: $220.8M quarterly revenue, +14.0% annual growth, and a P/E of 35.70 on a $1.9B market cap.

UTI's Chief Academic Officer sells 52,671 shares for $1,951,021.39; reduces stake 58.4% at $37.04 blended average.

Smith Sherrell executed 2 separate sales totaling 52,671 shares for $1,951,021.39 on 2026-03-02, reducing his post-transaction holdings to 37,474 shares—a 58.4% reduction from the pre-transaction 90,145 shares. The blended average sale price of $37.04 sits near the 52-week high of $37.50 and represents a 3.4% premium to the current price of $35.82, which has risen 23.6% over the past 30 days and 37.4% over 90 days. Across Sherrell's prior trades at UTI specifically, only 1 of 5 prior sells registered a negative 90-day return (well-timed), indicating limited historical precision in his sale execution at this ticker. The company's fundamentals remain solid—revenue of $220,844,000.00, net income of $12,827,000.00, and annual growth of 14.0%—though the P/E of 36.55 reflects elevated valuation; the substantial reduction in holdings merits monitoring alongside recent strong price momentum.

EVP Smith Sherrell sells 49,695 shares at $27.85 avg for $1,384,071.82 at UTI; reduces holdings 22.9%.

Smith Sherrell, EVP and Chief Academic Officer at Universal Technical Institute, executed 3 separate sales totaling 49,695 shares for $1,384,071.82 on March 19–20, 2025, at prices ranging from $26.68 to $27.94 (blended average $27.85). This sale reduced his holdings from 217,358 shares to 167,663 shares, representing a -22.9% reduction in his position. The timing occurs as the stock is down 10.7% from its 52-week high of $29.65 and down 9.1% over the past 30 days, though the company maintains solid fundamentals with revenue growth of +20.6% year-over-year and a market cap of $1.4B. The sale represents a material reduction in insider ownership and occurs in a near-term downtrend, but with only 3 recent same-ticker transactions (all on March 17–18) pending outcome measurement, there is no established pattern yet to distinguish whether this reflects scheduled program activity or discretionary positioning.

EVP Smith Sherrell sold 46,773 shares of UTI for $1,248,640.06 across 3 transactions (2025-03-17/18)

Smith Sherrell, Chief Academic Officer, executed 3 separate sales totaling 46,773 shares for $1,248,640.06 at an average price of $26.70, reducing his holdings by 46,773 shares (from 264,131 to 217,358 shares, a -17.7% reduction vs pre-transaction holdings). The sales occurred at $26.68–$27.27, near the current price of $27.98 and within 5.6% of the 52-week high of $29.65. UTI's fundamentals are robust: FY revenue growth of +20.6%, quarterly revenue of $201,429,000.00, net income of $22,153,000.00, and a P/E of 28.26 reflecting a market cap of $1,521,320,473.78. Sherrell's cross-ticker track record shows 2 prior open-market sells with an immeasurable timing pattern (0 of 0 prior sells met the well-timed criterion at the 90-day mark); his prior trades at UTI occurred on 2025-03-19 (outcome not yet measurable). The filing itself contains no flags indicating a 10b5-1 trading plan or other scheduled arrangement; absent such context, this represents a discretionary open-market sale of a meaningful portion of holdings during a period of strong company performance and near-peak valuation.